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Revised diagnostic criteria for neurofibromatosis type 1 and
Legius syndrome: an international consensus recommendation
Eric Legius 1,85✉, Ludwine Messiaen2,85, Pierre Wolkenstein3,85, Patrice Pancza4,85, Robert A. Avery5, Yemima Berman6,
Jaishri Blakeley7, Dusica Babovic-Vuksanovic8, Karin Soares Cunha9, Rosalie Ferner10, Michael J. Fisher11, Jan M. Friedman12,
David H. Gutmann13, Hildegard Kehrer-Sawatzki14, Bruce R. Korf2, Victor-Felix Mautner15, Sirkku Peltonen16,17, Katherine A. Rauen18,
Vincent Riccardi19, Elizabeth Schorry20, Anat Stemmer-Rachamimov21, David A. Stevenson22, Gianluca Tadini23, Nicole J. Ullrich24,
David Viskochil25, Katharina Wimmer26, Kaleb Yohay27, International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-
DC)*, Susan M. Huson28,85, D. Gareth Evans29,85 and Scott R. Plotkin30,85
PURPOSE: By incorporating major developments in genetics, ophthalmology, dermatology, and neuroimaging, to revise the
diagnostic criteria for neurofibromatosis type 1 (NF1) and to establish diagnostic criteria for Legius syndrome (LGSS).
METHODS: We used a multistep process, beginning with a Delphi method involving global experts and subsequently involving
non-NF experts, patients, and foundations/patient advocacy groups.
RESULTS: We reached consensus on the minimal clinical and genetic criteria for diagnosing and differentiating NF1 and LGSS,
which have phenotypic overlap in young patients with pigmentary findings. Criteria for the mosaic forms of these conditions are
also recommended.
CONCLUSION: The revised criteria for NF1 incorporate new clinical features and genetic testing, whereas the criteria for LGSS were
created to differentiate the two conditions. It is likely that continued refinement of these new criteria will be necessary as
investigators (1) study the diagnostic properties of the revised criteria, (2) reconsider criteria not included in this process, and (3)
identify new clinical and other features of these conditions. For this reason, we propose an initiative to update periodically the
diagnostic criteria for NF1 and LGSS.
Genetics in Medicine (2021) 23:1506–1513; https://doi.org/10.1038/s41436-021-01170-5
INTRODUCTION
Nomenclature and history
Neurofibromatosis type 1 (NF1; OMIM 613113), inherited in an
autosomal dominant pattern, is characterized by multiple café-au-
lait macules (CALMs), skinfold freckling (more correctly termed
lentiginous macules since they occur in non–sun exposed areas),
iris Lisch nodules, tumors of the nervous system, and other
features.1,2 Disease manifestations can occur in any body system.
There is a significantly increased risk of certain cancers, including
female breast cancer <50 years, malignant peripheral nerve sheath
tumors (MPNSTs), and brain tumors.3 The modern history of
nomenclature of neurofibromatosis started in 1987 with the
National Institutes of Health (NIH) Consensus Development
Conference on Neurofibromatosis.4 Until that time there had
been confusion in the literature as to whether bilateral vestibular
schwannomas (previously termed acoustic neuromas) were a
feature of NF1 or a distinct entity. Riccardi laid the groundwork for
the NIH consensus criteria by proposing a numerical classification
system based on the presence/absence of CALMs and skinfold
freckling, specific eye signs, neurofibromas, and complications
specific to each type.5 The mapping of the NF1 gene to
chromosome 176 and the NF2 gene to chromosome 227 allowed
the consensus conference to establish diagnostic criteria for the
two conditions (Table S1). The 1988 panel recognized that “[p]
atients who do not fit into the NF1 or NF2 group by clinical or
genetic criteria may, in the future, constitute the basis for
establishing additional types of NF.”4
The NIH criteria include the most frequent disease manifesta-
tions (CALMs, freckling, neurofibromas, and Lisch nodules)
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alongside disease complications typical of NF1. Since 1987 there
has been one formal review of the NF1 criteria by the Clinical Care
Advisory Board of the National Neurofibromatosis Foundation
(now the Children’s Tumor Foundation).8 No criteria alterations
were suggested.
The NF1 gene was cloned in 1990.9,10 Subsequent cell biology
studies have found that neurofibromin, the NF1 gene product,
largely operates as a GTPase-activating protein (GAP) that
negatively regulates the RAS/MAPK pathway activity by accelerat-
ing the hydrolysis of RAS-bound GTP.1 Cell biology advances and
animal models have led to the identification of MEK inhibitors as a
treatment for plexiform neurofibromas.11 In April 2020, selumeti-
nib was approved by the US Food and Drug Administration for
treatment of children with NF1-related symptomatic plexiform
neurofibroma.11
NF1 was the first human condition mapped to the RAS pathway
but subsequently other conditions have been shown to be caused
by pathogenic variants (PVs) in RAS pathway genes, including
Noonan, Costello, and cardiofaciocutaneous syndromes.12
Together, this group of conditions is referred to as RASopathies.
Legius syndrome (LGSS; OMIM 611431) is the RASopathy with the
most overlap to NF1.13 LGSS, inherited in an autosomal dominant
pattern, is characterized by multiple CALMs similar to NF1 with or
without skinfold freckling, caused by heterozygous PVs in SPRED1,
located on chromosome 15.13,14 Further studies have shown that
SPRED1 PVs account for 1% of sporadic cases and 19% of familial
cases with pigmentary features of NF1 (CALMs and freckling)
only.14 No individuals with LGSS have developed Lisch nodules,
neurofibromas, or other complications of NF1. LGSS could be
clinically diagnosed as NF1 using the NIH criteria (50% satisfy the
criteria14) but it has a different natural history. The condition is less
frequent than NF1 with an estimated birth prevalence of 1/
46,000–1/75,000 (4% of individuals followed at a neurofibroma-
tosis clinic),15 compared to 1/2,000–1/3,000 for NF1.16
The identification of LGSS highlights an important limitation of
the NIH NF1 clinical diagnostic criteria. In addition, other
conditions with overlapping phenotypes but distinct natural
histories have been identified or better defined (e.g., segmental/
mosaic NF117 and constitutional mismatch repair deficiency
[CMMRD] syndrome18) and new potential criteria for NF1 have
been identified (e.g., choroidal anomalies19 and nevus anemi-
cus20). Finally, NF1 genetic testing has become clinically available
with a high detection rate21 and clinically useful
genotype–phenotype correlations have been identified.22 With
sponsorship from the Children’s Tumor Foundation (CTF), an
international panel of neurofibromatosis and schwannomatosis
experts was assembled in 2017 and charged with reviewing
diagnostic criteria for NF1, NF2, and schwannomatosis. The work
on NF2 and schwannomatosis is presented in another paper.
MATERIALS AND METHODS
A modified Delphi process was used to reach consensus on revised
diagnostic criteria (Supplementary Fig. 1). A steering committee (seven
experts) reviewed the literature and generated the statements for the two
rounds of the Delphi process (data S1, S2, S3, S4, S5, and Supplemental
Material and Methods) regarding potential changes to NF1 diagnostic
criteria. The Steering Committee actively sought input from patients,
families, and advocates regarding the proposed criteria and the new
diagnostic criteria were finalized in January 2020. All clinical images are
used with consent from the patient/patient’s parent.
RESULTS
Development of initial proposals to revision of NF1 diagnostic
criteria
The steering committee evaluated the literature for clinical and/or
genetic features that could reliably identify and distinguish NF1,
mosaic NF1, LGSS, and mosaic LGSS. Among the clinical features
considered were presence of characteristic tumors such as
neurofibromas or gliomas; presence of cutaneous findings
including CALMs, skinfold freckling, juvenile xanthogranulomas,23
and nevus anemicus;20 presence of characteristic ophthalmologic
findings such as Lisch nodules and choroidal abnormalities;24
presence of characteristic osseous lesions such as sphenoid wing
dysplasia, scoliosis, anterolateral bowing of the lower leg,
pseudarthrosis;25 presence of focal areas of signal intensity (FASI)
detected by brain magnetic resonance image (MRI),26 and
presence of a family history. Among the molecular features
considered were identification of an NF1 and SPRED1 pathogenic
variant (PV) in unaffected tissue.
Modified Delphi process
Sixty-seven of 76 NF experts (89%) participated in the first Delphi
process by rating the 13 NF1 diagnostic criteria statements
(Supplementary Fig. 2). There was very high consensus (median
score= 10/10) for four proposed changes: revising criteria to
clearly define mosaic NF1; adding genetic diagnosis, without
implying that genetic testing is required or recommended for
diagnosis; replacing thinning of a long bone by anterolateral
bowing of the lower limb; and retaining the specified criteria
regarding neurofibromas, optic glioma, and Lisch nodules with
minor wording changes for the latter two criteria. There was high
consensus (median score= 7–9/10) for seven proposed changes:
revising the nomenclature to clearly distinguish NF1/LGSS from
NF2/schwannomatosis; clarifying which first-degree relatives meet
criteria for family history; combining CALMs and skinfold freckling
into a single criterion; naming individual long bones commonly
affected by congenital bowing and/or pseudarthrosis; and adding
juvenile xanthogranulomas, choroidal abnormalities, and dys-
trophic scoliosis to the revised criteria. There was no consensus
(median score= 4–6/10) for two proposed changes: adding nevus
anemicus and FASI to the revised criteria.
At the 2018 meeting in New York, working groups developed
nine revised statements concerning diagnostic criteria for discus-
sion, including discussion about changing the format of the
diagnostic criteria into a tiered system with A and B features. Fifty-
eight of 76 NF experts (76%) participated by rating the nine
revised statements (Supplementary Fig. 3). There was very high
consensus (more than 80% agreement) for four proposed
changes: adding a new criterion of genetic diagnosis, and
recommending genetic testing for patients with segmental clinical
findings, for families with two affected siblings and clinically
unaffected parents, and for children who meet the criteria based
on pigmentary findings alone. There was high consensus
(agreement 60–80%) for three proposed changes: considering
genetic testing for individuals with multiple bilateral spinal nerve
neurofibromas without other features of NF1, requiring use of slit
lamp or indirect ophthalmoscopy for identification of Lisch
nodules, and including choroidal abnormalities as a diagnostic
criterion. Finally, there was more agreement to retain the current
format as opposed to selecting A/B criteria (71% agreement). In
total, 74/76 NF experts (97%) were involved in the revision process
(data S4).
Nine of 12 (75%) non-NF specialists responded to the survey
(data S5) and strongly agreed with the proposed changes to the
NF1 diagnostic criteria. The experts agreed that nonspecialists
would be able to use the revised criteria.
Proposed new diagnostic criteria for NF1 and LGSS
Ultimately, consensus was reached on the minimal clinical and
genetic criteria for diagnosing NF1 and LGSS. Final recommenda-
tions for NF1 are listed in Table 1 and for LGSS in Table 2.
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Proposed diagnostic criteria for mosaic NF1 and mosaic LGSS
The final recommendations for diagnostic criteria for mosaic NF1
are listed in Table 3, and for mosaic LGSS in Table 4. The criteria
allow for both a molecular and clinical diagnosis of mosaic NF1
and mosaic LGSS, although mosaic LGSS is very rare.27
DISCUSSION
In this paper, the results of an international, multispecialty effort to
revise the diagnostic criteria for NF1 and LGSS are presented. The
process extended over three years, reflecting the commitment to
involve a wide array of specialists, nonspecialists, patient advocacy
groups, patients, and family members into the process. The goal
was to incorporate clinical and genetic discoveries made since the
initial consensus conference into the revised criteria. We used a
modified Delphi approach to reach maximum consensus among
stakeholders with the understanding that complete agreement
was not a reasonable goal. A recurring theme during the process
was the challenge of balancing the expectations of different
medical specialties for diagnostic criteria. For example, some
specialists emphasized the importance of diagnosing children at a
young age to screen for important medical features (i.e., high
sensitivity) while others emphasized the need to avoid potential
misdiagnosis (i.e., high specificity). Ultimately, the group
attempted to choose criteria that balanced the needs of high
sensitivity and specificity. The Delphi process worked well in both
reaching consensus in some areas and highlighting the issues with
varying opinion for discussion at the meeting in New York.
Pigmentary findings alone are not specific for NF1
The current clinical diagnostic criteria have low sensitivity in
children since diagnostic signs appear progressively over time.1
Participants considered, but did not ultimately recommend,
combining pigmentary criteria (CALMs/skinfold freckling) into a
single criterion. Although combining would mean patients with
LGSS would not meet the criteria for NF1, it could potentially delay
diagnosis in children without access to molecular testing. To alert
clinicians to the differential diagnosis, an asterisk was added to the
diagnostic criteria for NF1 stating that if only pigmentary findings
are present, clinicians should consider alternative diagnoses,
including, but not limited to, LGSS, Noonan syndrome with
multiple lentigines, and CMMRD.
The challenge of distinguishing NF1 from LGSS based on
pigmentary findings was demonstrated by Messiaen et al.14 who
studied an anonymous cohort of 2,432 individuals referred for NF1
molecular diagnosis. An NF1 PV was identified in 1,114 individuals
and a SPRED1 PV in 33 (2.9% of PV-positive individuals). In the
subset of 1,098 individuals (45%) younger than seven years of age,
the NIH criteria showed sensitivity of 58.2% and specificity of
88.6% for the diagnosis of a PV in NF1 or SPRED1 (groups lumped
together). The positive predictive value (PPV) for the NIH criteria
was 80.5%, and the negative predictive value (NPV) 71.5%. At ≥7
years, the sensitivity of the NIH criteria increased to 85.3%,
specificity was 74.3%, PPV 75.8% and NPV 84.3%. To increase the
diagnostic rate in the age group <7 years and in the subgroup
with only CALMs and skinfold freckling (with or without a family
history) and no other clinical criteria, molecular diagnosis could be
considered to confirm a diagnosis of NF1 or LGSS.
Table 1. Revised diagnostic criteria for neurofibromatosis type 1 (NF1).
A: The diagnostic criteria for NF1 are met in an individual who does not have a parent diagnosed with NF1 if two or more of the following are present:
• Six or more café-au-lait macules over 5 mm in greatest diameter in prepubertal individuals and over 15 mm in greatest diameter in postpubertal
individualsa (Supplementary Fig. 6)
• Freckling in the axillary or inguinal regiona (Supplementary Fig. 7)
• Two or more neurofibromas of any type or one plexiform neurofibroma (Supplementary Fig. 8a, b)
• Optic pathway glioma (Supplementary Fig. 9)
• Two or more iris Lisch nodules identified by slit lamp examination or two or more choroidal abnormalities (CAs)—defined as bright, patchy nodules
imaged by optical coherence tomography (OCT)/near-infrared reflectance (NIR) imaging (Supplementary Fig. 10a, b)
• A distinctive osseous lesion such as sphenoid dysplasia,b anterolateral bowing of the tibia, or pseudarthrosis of a long bone (Supplementary Fig. 11)
• A heterozygous pathogenic NF1 variant with a variant allele fraction of 50% in apparently normal tissue such as white blood cells
B: A child of a parent who meets the diagnostic criteria specified in A merits a diagnosis of NF1 if one or more of the criteria in A are present
aIf only café-au-lait macules and freckling are present, the diagnosis is most likely NF1 but exceptionally the person might have another diagnosis such as
Legius syndrome. At least one of the two pigmentary findings (café-au-lait macules or freckling) should be bilateral.
bSphenoid wing dysplasia is not a separate criterion in case of an ipsilateral orbital plexiform neurofibroma.
Table 2. Diagnostic criteria for Legius syndrome.
A: The diagnostic criteria for Legius syndrome are met in an individual who does not have a parent diagnosed with Legius syndrome if the
following CRITERIA are present:
• Six or more café-au-lait macules (Supplementary Fig. 12) bilaterally distributed and no other NF1-related diagnostic criteria except for axillary
or inguinal frecklinga
• A heterozygous pathogenic variant in SPRED1 with a variant allele fraction of 50% in apparently normal tissue such as white blood cells
B: A child of a parent who meets the diagnostic criteria specified in A merits a diagnosis of Legius syndrome if one or more of the criteria in A are
present
aThe presence of fewer than six café-au-lait spots does not exclude Legius syndrome.
E. Legius et al.
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Clinicians should attend closely to typical pigmentary findings
to help distinguish between NF1 and mosaic NF1. Participants
recommended adding a clarification to the revised criteria
indicating that at least one of the two pigmentary findings
(CALM/freckling) should be bilateral. This should help reduce, but
will not completely eliminate, the misdiagnosis of NF1 in an
individual with segmental or generalized mosaic NF1. However, it
highlights the possibility of mosaic NF1 when pigmentary findings
are localized to one side of the body. In addition, CALMs or
freckling may not be seen in older individuals, in those with many
cutaneous neurofibromas, or in individuals with spinal neurofi-
bromatosis.28 The diagnosis is confirmed by genetic testing or the
finding of Lisch nodules/choroidal anomalies.
Choroidal abnormalities
Choroidal abnormalities were added as an ophthalmologic
criterion because of the high specificity and sensitivity for
NF119,29 and for the ability to differentiate NF1 from LGSS.19 In
the revised diagnostic criteria, either Lisch nodules or choroidal
abnormalities is sufficient for this criterion; choroidal abnormalities
were not included as a separate criterion since isolated
ophthalmologic findings, even if bilateral (e.g., an individual with
only two Lisch nodules and two choroidal abnormalities) are likely
to reflect mosaic NF1 rather than constitutional NF1.
Affected siblings and offspring no longer qualify as criterion for
NF1
Participants recommended changing “A first-degree relative
(parent, sibling, or offspring) with NF1 by the above criteria” to
“a parent with NF1 by the above criteria." Sibling was deleted
because if only siblings are affected, one should consider a
diagnosis of CMMRD.30 Offspring was omitted because if an adult
person only has one criterion aside from an offspring fulfilling
diagnostic criteria, then mosaic NF1 should be suspected in this
individual. Having a parent with NF1 by the above criteria will
correctly diagnose most offspring presenting with one of the
other diagnostic criteria as having NF1, although, occasional co-
occurrence of more than one distinct NF1/SPRED1 pathogenic
variant in a family has been reported.31
Genetic concepts of importance for revised diagnostic criteria
Criteria for pathogenicity of variants. Per recommendations by the
Human Genome Variation Society (HGVS), the term “mutation” has
been replaced by the more neutral term “variant.”32 These variants
and interpretation of variants are classified following criteria as
established by their professional society. The standards and
guidelines developed by the American College of Medical Genetics
and Genomics (ACMG), the Association for Molecular Pathology
(AMP), and the College of American Pathologists (CAP) have now
been implemented widely in laboratories offering clinical molecular
testing.33 Variants can be classified as benign (B), likely benign (LB),
of uncertain clinical significance (VUS), likely pathogenic (LP), or
pathogenic (P).33 This framework improves the interlaboratory
consistency of classification and allows for reclassification of a
variant once more data have become available. The term likely
pathogenic refers to those variants considered to have greater than
90% certainty to be disease causing. It is expected, as our
understanding of NF1 genetic variants increases, that the algorithms
to classify the variants will further be improved and refined, which is
especially important for those variants currently classified as VUS.
Table 3. Diagnostic criteria for mosaic neurofibromatosis type 1 (NF1).
The diagnostic criteria for mosaic NF1 are met in an individual if any of the following is present:
1. A pathogenic heterozygous NF1 variant with a variant allele fraction of significantly less than 50% in apparently normal tissue such as white
blood cells AND one other NF1 diagnostic criterion (except a parent fulfilling diagnostic criteria for NF1)
2. An identical pathogenic heterozygous NF1 variant in two anatomically independent affected tissues (in the absence of a pathogenic NF1
variant in unaffected tissue)a
3. A clearly segmental distribution of café-au-lait macules or cutaneous neurofibromas AND
a. Another NF1 diagnostic criterion (except a parent fulfilling diagnostic criteria for NF1)b
or
b. Child fulfilling diagnostic criteria for NF1
4. Only one NF1 diagnostic criterion from the following list: freckling in the axillary and inguinal region, optic pathway glioma, two or more Lisch
nodules or two or more choroidal abnormalities, distinctive osseous lesion typical for NF1, two or more neurofibromas or one plexiform
neurofibroma AND a child fulfilling the criteria for NF1
aNeurofibroma and overlying hyperpigmented skin count for one tissue only; different tissues originating from the same primary affected lesion count for
one tissue only.
bIf only café-au-lait macules and freckling are present, the diagnosis is most likely mosaic neurofibromatosis type 1 but rarely might be mosaic Legius
syndrome or constitutional mismatch repair deficiency (CMMRD) syndrome.
Table 4. Diagnostic criteria for mosaic Legius syndrome.
The diagnostic criteria for mosaic Legius syndrome are met in an individual if any of the following is present:
1. A heterozygous pathogenic SPRED1 variant with a variant allele fraction of significantly less than 50% in apparently normal tissue such as white
blood cells AND six or more café-au-lait macules
2. An identical pathogenic heterozygous SPRED1 variant in two independent affected tissues (in the absence of a pathogenic SPRED1 variant in
unaffected tissue)a
3. A clearly segmental distribution of café-au-lait macules AND a child fulfilling the criteria for Legius syndrome
aDifferent tissues originating from the same primary affected lesion count for one tissue only.
E. Legius et al.
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Pathogenic NF1 variants. NF1 PVs can be located across the
entire coding region as well as across noncoding regions and
include microdeletions spanning the NF1 gene and multiple
flanking genes; smaller intragenic copy-number variants; frame-
shift, nonsense and missense variants; splice site, exonic, and deep
intronic variants affecting normal splicing; in-frame deletions or
duplications of one to several codons; variants affecting the
translational start codon; complex insertion/deletion variants;
(balanced) translocations; and Alu/LINE insertions.34
A comprehensive approach, using dosage analysis to detect
copy-number variants, and DNA-based sequencing, detects a PV in
~90% of classic (i.e., having pigmentary features as well as
neurofibromas) well characterized nonfounder (i.e., second gen-
eration) NF1 patients. Detection rate and specificity is increased to
95–97% when an RNA-based sequencing approach, in addition to
dosage analysis, is applied.34 Detection rates will vary in
oligosymptomatic individuals or individuals with atypical pre-
sentation.14,35 Since genetic testing for NF1 PV is heavily biased
toward individuals with some aspect of the known NF1 phenotype
we might be missing individuals with very atypical presentations.
No NF1 inactivating variants have been reported in the
alternatively spliced exons of NF1 because these might be
associated with no or a different phenotype. Scrutiny of genome
or exome sequencing data in large cohorts of carefully
phenotyped patients might shed light on this issue.
NF1 PV alone is not sufficient for diagnosis
Diagnosis of NF1 is confirmed when an NF1 PV is identified in an
individual/fetus having either one or more of the other diagnostic
criteria fulfilled. As panel testing by next-generation sequencing
and exome/genome sequencing analysis is ordered with increas-
ing frequency in individuals with a variable set of clinical features,
some individuals have been found to carry an NF1 variant (P, LP,
VUS) in unaffected tissue such as blood, although NF1 was not
clinically suspected. NF1 experts agreed that identification of an
NF1 variant alone does not suffice to make a diagnosis of NF1 but
does require further clinical and genetic evaluation: the variant
must be confirmed as pathogenic using an orthogonal method;
further genetic analysis is required to verify if the variant is present
as a constitutional (germline), mosaic (which may result in a mild
phenotype), or somatic variant (e.g., due to clonal expansion in the
hematopoietic stem and progenitor cells of indeterminate
potential or secondary to therapy, hematological malignancy,
premalignancy, or circulating tumor cells36). Since only one other
criterion is required for a diagnosis of NF1 the NF1 variant has to
be pathogenic to fulfill the second criterion for diagnosis.
Including likely pathogenic variants in the diagnostic criteria will
unnecessarily reduce specificity.
Somatic second hit NF1 PVs are typically identified in every NF1-
associated tumor such as cutaneous and plexiform neurofibromas
as well as in tissues from distinctive nontumor lesions such as
CALMs,37 thereby resulting in biallelic NF1 activation (Supplemen-
tary Fig. 4).
Genetic mosaicism: mechanism, phenotypes, and implications for
genetic testing
As many as 30–50% of NF1 patients are sporadic or founder
patients, meaning they did not inherit the disorder from an
affected parent.1,2,8 It is important to raise awareness that a
proportion of founder patients will have the disorder due to an
NF1 variant acquired in a specific cell after fertilization.
These mosaic patients therefore carry the first hit NF1 variant
only in a subpopulation, as opposed to all body cells, unlike in
patients with constitutional NF1 where the NF1 variant is present
in the fertilized egg. The risk for transmission to the next
generation is <50% for an individual with mosaic NF1; however, if
the NF1 variant is transmitted to the next generation, offspring will
carry the variant in the germline and the overall clinical
presentation will usually be more severe. Depending on the
timing and types of progenitor cells affected externally visible
features may include pigmentary features only, cutaneous or
plexiform neurofibromas only, or a combination of both, and
affected body regions may range from multiple body regions
crossing the midline that may resemble a generalized phenotype,
to a single segment of the body not crossing the midline.38 Pure
gonadal mosaicism, with the somatic NF1 PVs present only in the
gonads, is, however, rare.39
Mosaic NF1 in a patient is confirmed when an individual with
features of NF1 carries a heterozygous NF1 PV in an unaffected
tissue such as blood but in significantly less than 100% of cells
(variant allele fraction [VAF] < 50%). Mosaic NF1 is also confirmed
if an identical first hit pathogenic NF1 variant is identified in two or
more anatomically unrelated affected lesions in the absence of
this PV in unaffected tissue such as blood.
Detection of the causal NF1 PVs in individuals with a mosaic/
segmental phenotype requires special attention to (1) the
sensitivity of the technology used to detect variants, as well as
(2) the type of cells to be analyzed in affected tissue if the variant
is not detectable in blood, i.e., melanocytes (but not keratinocytes
or fibroblasts) from CALMs37 or Schwann cells from the cutaneous
or plexiform neurofibromas.40
It is the responsibility of the laboratories to define and report
the criteria used for the orthogonal confirmation of the variants as
either constitutional/germline or mosaic.
Orthopedic criteria
In the 1987 criteria, the orthopedic criteria included “thinning of
the long bone cortex with or without pseudarthrosis.” In 2007,
rewording of this criterion was suggested25 since thinning of long
bone cortex is not the primary lesion. Rather, most children
present with anterolateral bowing of the lower limb and on X-ray
have medullary canal narrowing and cortical thickening at the
apex of the curve in the tibia and/or fibula.25 The bowing may or
may not progress to fracture and pseudarthrosis. Other long
bones have been reported with pseudarthrosis but this is rare.
Proposed features that were not included in the revised criteria
Some possible diagnostic criteria were not incorporated into the
revised criteria because of insufficient data on specificity and/or
sensitivity or other reasons. These criteria include FASI detected by
MRI (given concerns about their specificity and their disappear-
ance over time in some patients, the potential complications of
anesthesia in children in scans done for diagnostic evaluation),
nevus anemicus, and juvenile xanthogranuloma (Supplementary
Fig. 5; both features difficult to diagnose clinically for nonderma-
tologists and xanthogranuloma only present transiently). In
addition, participants decided not to include a comment on
different possible locations of skinfold freckling or comments on
spinal neurofibromas. Moving forward, it will be important to
collect prospective data on the diagnostic sensitivity and
specificity of these clinical findings for diagnosis.
Using the revised diagnostic criteria
It should be emphasized that clinicians do not necessarily need to
search for each of the clinical features described in the criteria. For
example, it is not recommended to perform biopsies or
examinations under general anesthesia only to confirm diagnostic
criteria. In the absence of molecular testing, serial observation will
confirm whether NF1 is present in most affected individuals. In
addition, one should be cautious to diagnose NF1 if neither CALMs
nor neurofibromas are present, because that would be suggestive
of mosaic NF1 or another unusual situation.
E. Legius et al.
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Revising the nomenclature of NF1
The term “neurofibromatosis” was derived from “neurofibroma,”
the term used by von Recklinghausen to describe the benign
nerve sheath tumor that is the hallmark of NF1.2 In 2007, an NF1-
like syndrome was linked to SPRED1 PVs.13 Subsequent authors
were concerned that any reference to NF1 in the name may
confuse parents and proposed the eponymous name Legius
syndrome, which has been widely adopted. During the discus-
sions, we considered having it as a NF1 subtype but, in the
absence of neurofibromas, it is inappropriate to consider it a type
of neurofibromatosis.
The aim of the revision process was to help professionals
distinguish between NF1 and LGSS early in life. Experts did not
endorse renaming NF1 since virtually all individuals with NF1
develop neurofibromas and since the name is established by use
and history. Ultimately for the syndrome associated with SPRED1,
experts agreed that nomenclature based on nosology or
pathogenesis did not improve understanding of the condition
and suggested retaining the name Legius syndrome since the
term is established and not misleading. We understand that a
more appropriate nomenclature is needed to rename neurofi-
bromatosis type 1, Legius syndrome, neurofibromatosis type 2,
and schwannomatosis. This will be one of the future tasks of the
steering committee.
Continued revision of the diagnostic criteria
The proposed criteria for diagnosis of NF1 and LGSS represent the
first coordinated attempt by our community to update the
diagnostic criteria since 1987. Given the challenge in organizing
the input of multiple experts, patients, and advocacy groups in
this process, it is unlikely that a major revision to the criteria will
be proposed in the near future. However, it is likely that
refinement of these diagnostic criteria will be necessary in the
future. For this reason, the CTF will sponsor an ongoing initiative
to evaluate and recommend proposed changes to the diagnostic
criteria for NF1 and LGSS. We anticipate that this group of experts
will meet periodically to solicit input from the community, to
review data relevant to diagnostic criteria, and will publish its
consensus recommendations periodically for use by the larger
community.
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